Oxford Immunotec Announces Appointment of Richard Alteri as Chief Financial Officer

OXFORD, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Oxford Immunotec Ltd. an immunology focused diagnostic company, announces the appointment of Richard (Rick) Alteri as Chief Financial Officer (CFO).

Prior to joining Oxford Immunotec, Mr. Altieri was Vice President and Chief Financial Officer of Salient Surgical Technologies, Inc. a medical technology company that develops and markets surgical advanced energy products. At Salient, he led all financing activities, prepared to take the company public and played a key role in the ultimate sale of the company to Medtronic. Before Salient, Rick was Senior Vice President of Finance and Chief Financial Officer of Straumann USA, a global leader in the field of implant dentistry and dental tissue regeneration. Previously, he was Vice President and Chief Financial Officer of Mitek Surgical Products, Inc., where he played a key role in the sale of the company to Johnson & Johnson. As part of the J&J family he was instrumental in Mitek’s subsequent growth into a leader in the field of surgical sports medicine. Rick is a CPA and earned his BS degree in Accounting from Northeastern University and an MBA from Babson College.

“I am very pleased that Rick has joined the organization,” commented Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “Rick’s leadership and background with building high growth medical technology companies will be a tremendous asset to the organization as we continue to grow rapidly.”

- Ends-

Notes to Editors:

About Oxford Immunotec

www.oxfordimmunotec.com

Oxford Immunotec Ltd., the T cell measurement company, is headquartered near Oxford, UK; its US operations are based in Marlborough, MA. The company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.

T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response to infection and could be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT®.TB test

The T-SPOT.TB test is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and is the first product from Oxford Immunotec using T-SPOT technology. The product offers unrivalled sensitivity with results unaffected by a patient’s immune status. The

T-SPOT.TB test is approved for sale in Europe, USA, Canada and over 40 other countries worldwide and is designed to replace the 115 year old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market exceeding $1bn.

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.



CONTACT:

At Oxford Immunotec:
Dr Peter Wrighton-Smith, CEO
Tel: +44 (0)1235 442780
Fax: +44 (0)1235 442781
Email: [email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases

MEDIA:

Logo
 Logo

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.